BACKGROUND: Clostridium difficile-associated diarrhea (CDAD) is an important infection in hospital settings. Its impact on outpatient care has not been well defined. OBJECTIVE: To examine risk factors of ambulatory cancer patients with CDAD. DESIGN: Case-control study. SETTING: Memorial Sloan-Kettering Cancer Center, a tertiary-care hospital. METHODS: Cases of CDAD among oncology outpatients from January 1999 through December 2000 were'identified via positive C. difficile toxin assay results on stool specimens sent from clinics or the emergency department. A 1:3 matched case-control study examined exposures associated with CDAD. RESULTS: Forty-eight episodes of CDAD were identified in cancer outpatients. The mean age was 51 years; 44% were female. Forty-one (85%) had received antibiotics within 60 days of diagnosis, completing courses a median of 16.5 days prior to diagnosis. Case-patients received longer courses of first-generation cephalosporins (4.8 vs 3.2 days; P = .03) and fluoroquinolones (23.6 vs 8 days; P < .01) than did control-patients. Those receiving clindamycin were 3.9-fold more likely to develop CDAD (P < .01). For each additional day of clindamycin or third-generation cephalosporin exposure, patients were 1.29- and 1.26-fold more likely to develop CDAD (P < .01 and .04, respectively). The 38 CDAD patients hospitalized during the risk period (79.2%) spent more time as inpatients than did control-patients (19.3 vs 9.7 days; P < .001). CONCLUSIONS: Antibiotic use, especially with cephalosporins and clindamycin, and prolonged hospitalization contributed to the development of CDAD. Outpatient CDAD appears to be most strongly related to inpatient exposures; reasons for the delayed development of symptoms are unknown.
BACKGROUND:Clostridium difficile-associated diarrhea (CDAD) is an important infection in hospital settings. Its impact on outpatient care has not been well defined. OBJECTIVE: To examine risk factors of ambulatory cancerpatients with CDAD. DESIGN: Case-control study. SETTING: Memorial Sloan-Kettering Cancer Center, a tertiary-care hospital. METHODS: Cases of CDAD among oncology outpatients from January 1999 through December 2000 were'identified via positive C. difficile toxin assay results on stool specimens sent from clinics or the emergency department. A 1:3 matched case-control study examined exposures associated with CDAD. RESULTS: Forty-eight episodes of CDAD were identified in cancer outpatients. The mean age was 51 years; 44% were female. Forty-one (85%) had received antibiotics within 60 days of diagnosis, completing courses a median of 16.5 days prior to diagnosis. Case-patients received longer courses of first-generation cephalosporins (4.8 vs 3.2 days; P = .03) and fluoroquinolones (23.6 vs 8 days; P < .01) than did control-patients. Those receiving clindamycin were 3.9-fold more likely to develop CDAD (P < .01). For each additional day of clindamycin or third-generation cephalosporin exposure, patients were 1.29- and 1.26-fold more likely to develop CDAD (P < .01 and .04, respectively). The 38 CDADpatients hospitalized during the risk period (79.2%) spent more time as inpatients than did control-patients (19.3 vs 9.7 days; P < .001). CONCLUSIONS: Antibiotic use, especially with cephalosporins and clindamycin, and prolonged hospitalization contributed to the development of CDAD. OutpatientCDAD appears to be most strongly related to inpatient exposures; reasons for the delayed development of symptoms are unknown.
Authors: D G Levy; A Stergachis; L V McFarland; K Van Vorst; D J Graham; E S Johnson; B J Park; D Shatin; J C Clouse; G W Elmer Journal: Clin Ther Date: 2000-01 Impact factor: 3.393
Authors: E Blot; M-C Escande; D Besson; F Barbut; C Granpeix; B Asselain; M-C Falcou; P Pouillart Journal: J Hosp Infect Date: 2003-03 Impact factor: 3.926
Authors: Kimberly G Blumenthal; Erin E Ryan; Yu Li; Hang Lee; James L Kuhlen; Erica S Shenoy Journal: Clin Infect Dis Date: 2018-01-18 Impact factor: 9.079
Authors: Kimberly G Blumenthal; Nicolas M Oreskovic; Xiaoqing Fu; Fatma M Shebl; Christian M Mancini; Jennifer M Maniates; Rochelle P Walensky Journal: Am J Manag Care Date: 2020-04 Impact factor: 2.229
Authors: J Freeman; M P Bauer; S D Baines; J Corver; W N Fawley; B Goorhuis; E J Kuijper; M H Wilcox Journal: Clin Microbiol Rev Date: 2010-07 Impact factor: 26.132
Authors: Jacob E Simmering; Linnea A Polgreen; David R Campbell; Joseph E Cavanaugh; Philip M Polgreen Journal: Infect Control Hosp Epidemiol Date: 2015-06-15 Impact factor: 3.254
Authors: Courtney R Murphy; Taliser R Avery; Erik R Dubberke; Susan S Huang Journal: Infect Control Hosp Epidemiol Date: 2011-11-11 Impact factor: 3.254
Authors: Lillian Sung; Richard Aplenc; Todd A Alonzo; Robert B Gerbing; Thomas Lehrnbecher; Alan S Gamis Journal: Blood Date: 2013-03-07 Impact factor: 22.113
Authors: Erik R Dubberke; Anne M Butler; Bala Hota; Yosef M Khan; Julie E Mangino; Jeanmarie Mayer; Kyle J Popovich; Kurt B Stevenson; Deborah S Yokoe; L Clifford McDonald; John Jernigan; Victoria J Fraser Journal: Infect Control Hosp Epidemiol Date: 2009-06 Impact factor: 3.254